New pharmaceutical treatment of gastric MALT lymphoma: Anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib

Masahiko Nakamura, Tetsufumi Takahashi, Hidenori Matsui, Shinichi Takahashi, Somay Y. Murayama, Hidekazu Suzuki, Kanji Tsuchimoto

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

In addition to eradication of Helicobacter pylori, chemotherapy with anticancer agents, and radiation therapy, the treatment with molecular target drugs including rituximab, a CD20 antagonist, is one of the promising new regimens. The mucosa-associated lymphoid tissue (MALT) lymphoma is histologically characterized by rich distribution of the microvascular network consisting of the immature capillaries, lymphatics and venules, and this microvascular network could be the target of the new pharmacotherapy in addition to the direct action on the accumulated B lymphocytes. We have established the animal model of the gastric MALT lymphoma by the Helicobacter heilmannii (H. heilmannii) peroral infection of C57BL/6 mice. The disease induced by this model is very similar to the human counterpart, because of the lymphoepithelial lesion characteristic of the human MALT lymphoma as well as the rich vascularization and localization of vascular endothelial growth factor (VEGF) and its receptors, Flt-1, Flk-1 and Flt-4. By administering VEGF receptor antibodies or celecoxib, one of the cyclooxygenase 2 inhibitors, we were able to induce a significant decrease in the size of the tumor and the apoptotic changes of the endothelial cells of the microvascular network. These antiangiogenic strategies were suggested to be candidates for the new pharmacological treatment of gastric MALT lymphoma, when other treatments are not effective.

Original languageEnglish
Pages (from-to)1097-1103
Number of pages7
JournalCurrent Pharmaceutical Design
Volume20
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Celecoxib
Marginal Zone B-Cell Lymphoma
Vascular Endothelial Growth Factor Receptor
Gastric Mucosa
Microvessels
Antibodies
Pharmaceutical Preparations
Helicobacter heilmannii
Vascular Endothelial Growth Factor Receptor-3
Drug Therapy
Lymphatic Vessels
Cyclooxygenase 2 Inhibitors
Therapeutics
Inbred C57BL Mouse
Helicobacter pylori
Antineoplastic Agents
B-Lymphocytes
Radiotherapy
Endothelial Cells
Animal Models

Keywords

  • Angiogenesis
  • Celecoxib
  • Flk-1
  • Flt-1
  • Flt-4
  • Gastric MALT lymphoma
  • Lymphangiogenesis
  • VEGF

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

New pharmaceutical treatment of gastric MALT lymphoma : Anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib. / Nakamura, Masahiko; Takahashi, Tetsufumi; Matsui, Hidenori; Takahashi, Shinichi; Murayama, Somay Y.; Suzuki, Hidekazu; Tsuchimoto, Kanji.

In: Current Pharmaceutical Design, Vol. 20, No. 7, 2014, p. 1097-1103.

Research output: Contribution to journalArticle

Nakamura, M, Takahashi, T, Matsui, H, Takahashi, S, Murayama, SY, Suzuki, H & Tsuchimoto, K 2014, 'New pharmaceutical treatment of gastric MALT lymphoma: Anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib', Current Pharmaceutical Design, vol. 20, no. 7, pp. 1097-1103. https://doi.org/10.2174/13816128113199990420
Nakamura, Masahiko ; Takahashi, Tetsufumi ; Matsui, Hidenori ; Takahashi, Shinichi ; Murayama, Somay Y. ; Suzuki, Hidekazu ; Tsuchimoto, Kanji. / New pharmaceutical treatment of gastric MALT lymphoma : Anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib. In: Current Pharmaceutical Design. 2014 ; Vol. 20, No. 7. pp. 1097-1103.
@article{ba2a54222aba46ae9ad83bad5a6b3388,
title = "New pharmaceutical treatment of gastric MALT lymphoma: Anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib",
abstract = "In addition to eradication of Helicobacter pylori, chemotherapy with anticancer agents, and radiation therapy, the treatment with molecular target drugs including rituximab, a CD20 antagonist, is one of the promising new regimens. The mucosa-associated lymphoid tissue (MALT) lymphoma is histologically characterized by rich distribution of the microvascular network consisting of the immature capillaries, lymphatics and venules, and this microvascular network could be the target of the new pharmacotherapy in addition to the direct action on the accumulated B lymphocytes. We have established the animal model of the gastric MALT lymphoma by the Helicobacter heilmannii (H. heilmannii) peroral infection of C57BL/6 mice. The disease induced by this model is very similar to the human counterpart, because of the lymphoepithelial lesion characteristic of the human MALT lymphoma as well as the rich vascularization and localization of vascular endothelial growth factor (VEGF) and its receptors, Flt-1, Flk-1 and Flt-4. By administering VEGF receptor antibodies or celecoxib, one of the cyclooxygenase 2 inhibitors, we were able to induce a significant decrease in the size of the tumor and the apoptotic changes of the endothelial cells of the microvascular network. These antiangiogenic strategies were suggested to be candidates for the new pharmacological treatment of gastric MALT lymphoma, when other treatments are not effective.",
keywords = "Angiogenesis, Celecoxib, Flk-1, Flt-1, Flt-4, Gastric MALT lymphoma, Lymphangiogenesis, VEGF",
author = "Masahiko Nakamura and Tetsufumi Takahashi and Hidenori Matsui and Shinichi Takahashi and Murayama, {Somay Y.} and Hidekazu Suzuki and Kanji Tsuchimoto",
year = "2014",
doi = "10.2174/13816128113199990420",
language = "English",
volume = "20",
pages = "1097--1103",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - New pharmaceutical treatment of gastric MALT lymphoma

T2 - Anti-angiogenesis treatment using VEGF receptor antibodies and celecoxib

AU - Nakamura, Masahiko

AU - Takahashi, Tetsufumi

AU - Matsui, Hidenori

AU - Takahashi, Shinichi

AU - Murayama, Somay Y.

AU - Suzuki, Hidekazu

AU - Tsuchimoto, Kanji

PY - 2014

Y1 - 2014

N2 - In addition to eradication of Helicobacter pylori, chemotherapy with anticancer agents, and radiation therapy, the treatment with molecular target drugs including rituximab, a CD20 antagonist, is one of the promising new regimens. The mucosa-associated lymphoid tissue (MALT) lymphoma is histologically characterized by rich distribution of the microvascular network consisting of the immature capillaries, lymphatics and venules, and this microvascular network could be the target of the new pharmacotherapy in addition to the direct action on the accumulated B lymphocytes. We have established the animal model of the gastric MALT lymphoma by the Helicobacter heilmannii (H. heilmannii) peroral infection of C57BL/6 mice. The disease induced by this model is very similar to the human counterpart, because of the lymphoepithelial lesion characteristic of the human MALT lymphoma as well as the rich vascularization and localization of vascular endothelial growth factor (VEGF) and its receptors, Flt-1, Flk-1 and Flt-4. By administering VEGF receptor antibodies or celecoxib, one of the cyclooxygenase 2 inhibitors, we were able to induce a significant decrease in the size of the tumor and the apoptotic changes of the endothelial cells of the microvascular network. These antiangiogenic strategies were suggested to be candidates for the new pharmacological treatment of gastric MALT lymphoma, when other treatments are not effective.

AB - In addition to eradication of Helicobacter pylori, chemotherapy with anticancer agents, and radiation therapy, the treatment with molecular target drugs including rituximab, a CD20 antagonist, is one of the promising new regimens. The mucosa-associated lymphoid tissue (MALT) lymphoma is histologically characterized by rich distribution of the microvascular network consisting of the immature capillaries, lymphatics and venules, and this microvascular network could be the target of the new pharmacotherapy in addition to the direct action on the accumulated B lymphocytes. We have established the animal model of the gastric MALT lymphoma by the Helicobacter heilmannii (H. heilmannii) peroral infection of C57BL/6 mice. The disease induced by this model is very similar to the human counterpart, because of the lymphoepithelial lesion characteristic of the human MALT lymphoma as well as the rich vascularization and localization of vascular endothelial growth factor (VEGF) and its receptors, Flt-1, Flk-1 and Flt-4. By administering VEGF receptor antibodies or celecoxib, one of the cyclooxygenase 2 inhibitors, we were able to induce a significant decrease in the size of the tumor and the apoptotic changes of the endothelial cells of the microvascular network. These antiangiogenic strategies were suggested to be candidates for the new pharmacological treatment of gastric MALT lymphoma, when other treatments are not effective.

KW - Angiogenesis

KW - Celecoxib

KW - Flk-1

KW - Flt-1

KW - Flt-4

KW - Gastric MALT lymphoma

KW - Lymphangiogenesis

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84895156862&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895156862&partnerID=8YFLogxK

U2 - 10.2174/13816128113199990420

DO - 10.2174/13816128113199990420

M3 - Article

C2 - 23782142

AN - SCOPUS:84895156862

VL - 20

SP - 1097

EP - 1103

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 7

ER -